Two Sigma Advisers
CRVS icon

Two Sigma Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

Two Sigma Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,900
Closed -$146K – 519
2025
Q4 		$146K Sell
18,900
-142,700
-88% -$1.13M ﹤0.01% 2171
2025
Q3 		$1.19M Sell
161,600
-51,100
-24% -$262K ﹤0.01% 1374
2025
Q2 		$851K Sell
212,700
-23,700
-10% -$86.2K ﹤0.01% 1518
2025
Q1 		$752K Buy
236,400
+218,500
+1,221% +$1.03M ﹤0.01% 1602
2024
Q4 		$95.8K Sell
17,900
-43,400
-71% -$324K ﹤0.01% 2224
2024
Q3 		$324K Sell
61,300
-52,100
-46% -$187K ﹤0.01% 1881
2024
Q2 		$206K Sell
113,400
-71,700
-39% -$134K ﹤0.01% 2207
2024
Q1 		$329K Sell
185,100
-50,500
-21% -$105K ﹤0.01% 2037
2023
Q4 		$415K Sell
235,600
-13,300
-5% -$19.4K ﹤0.01% 1990
2023
Q3 		$363K Buy
248,900
+70,100
+39% +$148K ﹤0.01% 1915
2023
Q2 		$409K Sell
178,800
-8,500
-5% -$17.7K ﹤0.01% 1877
2023
Q1 		$170K Sell
187,300
-73,000
-28% -$57K ﹤0.01% 2297
2022
Q4 		$221K Sell
260,300
-219,800
-46% -$195K ﹤0.01% 2156
2022
Q3 		$393K Buy
480,100
+106,700
+29% +$102K ﹤0.01% 1946
2022
Q2 		$370K Sell
373,400
-43,800
-10% -$53.7K ﹤0.01% 2051
2022
Q1 		$684K Sell
417,200
-346,200
-45% -$634K ﹤0.01% 1828
2021
Q4 		$1.84M Buy
+763,400
New +$2.96M ﹤0.01% 1242
2021
Q3 		– Sell
-288,300
Closed -$770K – 2477
2021
Q2 		$770K Sell
288,300
-3,700
-1% -$10.2K ﹤0.01% 1754
2021
Q1 		$899K Buy
+292,000
New +$1.05M ﹤0.01% 1714
2020
Q3 		– Sell
-36,880
Closed -$100K – 2437
2020
Q2 		$100K Buy
36,880
+8,000
+28% +$23.6K ﹤0.01% 2357
2020
Q1 		$61K Buy
28,880
+12,300
+74% +$49.9K ﹤0.01% 2361
2019
Q4 		$90K Buy
+16,580
New +$58K ﹤0.01% 2258

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Advisers's CRVS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 18,900 shares — an estimated $146K sold.

Two Sigma Advisers first reported a position in CRVS in Q4 2019 and held it in 22 quarters. The position peaked at $1.84M in Q4 2021. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 18,900 Corvus Pharmaceuticals shares in Q1 2026, an estimated $146K.
  • Two Sigma Advisers first reported a position in Corvus Pharmaceuticals in Q4 2019 and held it in 22 quarters.
  • Two Sigma Advisers's Corvus Pharmaceuticals position peaked at $1.84M in Q4 2021.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.